Patent · US Active

Dosing regimen for a selective S1P1 receptor agonist

US11771683B2 · kind B2 · utility

0Cited by

16References

15Claims

0Family size

Assignee

Actelion Pharmaceuticals Ltd. · CH

Inventors

Jasper Dingemanse · Allschwil, CH
Matthias Hoch · Harston, GB
Andreas Krause · Frankfurt am Main, DE

Key dates

Filing date	Nov 5, 2020
Grant date	Oct 3, 2023
Priority date	—
Expiry date	Nov 5, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.